(A) V. harveyi AI-2 luminescence assay in the presence of
the purified fractions containing AI-2 (AI-2F) and AI-3 (AI-3F), in
vitro synthesized AI-2 (AI-2S) (10 and 100 μM), and PC medium prepared
with 86-24 (positive control), DH5α, and VS94. (B)
Transcription of LEE1::lacZ in fresh medium (M), in the
presence of the purified fractions AI-2 and AI-3, and in in vitro
synthesized AI-2. (C) Western blot of secreted proteins from strain
86-24, VS94, VS94 + 100 μM of AI-2S, VS94 + 50 μM of Epi (Sigma), and
VS94 + 4 μM of AI-3. (D) Electrospray mass spectrometry of the
AI-3 purified fraction. (E) Transcription of
LEE1::lacZ in fresh medium (M), in the presence of AI-3 (4
μM), and in AI-2S (100 μM). (F) Transcription of
LEE1::lacZ in fresh medium (LB), PC medium with strain 86-24
(PC-WT), PC medium with strain VS94 (PC-luxS), and PC medium with an E.
coli entA mutant (PC-entA). (G) Transcription of
qseBC::lacZ in a luxS mutant in the presence of
AI-3 (4 μM) and AI-2S (100 μM). (H) Transcription of
flhDC::lacZ in a luxS or qseC mutant
background in the presence of AI-3 (4 μM) or Epi (E; 50 μM).